Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Resectable Malignant Mesothelioma Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

NCT02592551
View directory record Official record
Conditions
Mesothelioma
Interventions
MEDI4736, Tremelimumab, no other name
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Jul 21, 2026, 9:38 AM EDT
Completed Phase 1 Interventional

Dasatinib in Resectable Malignant Pleural Mesothelioma

NCT00652574
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Dasatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Jul 21, 2026, 9:38 AM EDT
Completed Phase 1 Interventional

Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

NCT00571298
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Extrapleural pneumonectomy (EPP), Cisplatin, gemcitabine, amifostine, sodium thiosulfate, Pleurectomy/Decortication
Procedure · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Jul 21, 2026, 9:38 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

NCT03228537
View directory record Official record
Conditions
Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7
Interventions
Atezolizumab, Cisplatin, Extrapleural Pneumonectomy, Pemetrexed Disodium, Pleurectomy, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
175
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 122 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 9:38 AM EDT
Terminated Early Phase 1 Interventional

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

NCT04213794
View directory record Official record
Conditions
Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm, Recurrent Colon Carcinoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Gastric Carcinoma, Recurrent Liposarcoma, Recurrent Malignant Mesothelioma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Rectal Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Sarcoma, Refractory Colon Carcinoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Fallopian Tube Carcinoma, Refractory Gastric Carcinoma, Refractory Liposarcoma, Refractory Malignant Mesothelioma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Refractory Rectal Carcinoma, Refractory Rhabdomyosarcoma, Refractory Sarcoma, Resectable Liposarcoma, Resectable Malignant Mesothelioma, Resectable Sarcoma
Interventions
Cisplatin, Cytoreductive Surgery, Doxorubicin, Hyperthermic Intraperitoneal Chemotherapy, Sodium Thiosulfate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year to 25 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Jul 21, 2026, 9:38 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

NCT04162015
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Nivolumab, Pemetrexed, Cisplatin or Carboplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Jul 21, 2026, 9:38 AM EDT
Recruiting Phase 1 Interventional

CT-95 in Advanced Cancers Associated With Mesothelin Expression

NCT06756035
View directory record Official record
Conditions
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer
Interventions
CT-95
Drug
Lead sponsor
Context Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Denver, Colorado • Chicago, Illinois • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 9:38 AM EDT
Withdrawn Phase 1 Interventional

Pembrolizumab + Defactinib In Pleural Mesothelioma

NCT04201145
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Pembrolizumab, Defactinib
Drug
Lead sponsor
Raphael Bueno, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jul 21, 2026, 9:38 AM EDT
Recruiting Not applicable Interventional

Stereotactic Magnetic Resonance Guided Radiation Therapy

NCT04115254
View directory record Official record
Conditions
Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases, Prostate Cancer, Liver Metastases, Oligoprogressive Nodal Metastases, Metachronous Nodal Metastases, Synchronous Nodal Metastases, Mesothelioma, Spine Metastases, Brain Metastases, Borderline Resectable Pancreatic Carcinoma
Interventions
MR-guided Linac
Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jul 21, 2026, 9:38 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

NCT05932199
View directory record Official record
Conditions
Mesothelioma
Interventions
Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 21, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

NCT05041062
View directory record Official record
Conditions
Mesothelioma, Peritoneal Mesothelioma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Jul 21, 2026, 9:38 AM EDT
Terminated No phase listed Observational

Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma

NCT02613299
View directory record Official record
Conditions
Mesothelioma, Solitary Fibrous Tumor of the Pleura
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jul 21, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Jul 21, 2026, 9:38 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

NCT03918252
View directory record Official record
Conditions
Mesothelioma
Interventions
Nivolumab Injection, Ipilimumab Injection
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
3
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 21, 2026, 9:38 AM EDT
Terminated Phase 1 Interventional

A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

NCT02707666
View directory record Official record
Conditions
Pleural Mesothelioma
Interventions
Pembrolizumab, Cisplatin and Pemetrexed
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 21, 2026, 9:38 AM EDT
Terminated Phase 2 Interventional Results available

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

NCT02004028
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
VS-6063
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jul 21, 2026, 9:38 AM EDT